LY86-AS1: A Potential Drug Target and Biomarker (G285780)

Target Name: LY86-AS1

NCBI ID: G285780

LY86-AS1

Other Name(s): LY86-AS | LY86 antisense RNA 1 | LY86AS

LY86-AS1: A Potential Drug Target and Biomarker

LY86-AS1, also known as CD11b, is a cell surface glycoprotein that is expressed in various tissues and cell types, including human platelets, macrophages, and cancer cells. It is a potential drug target and biomarker for various diseases, including cancer, cardiovascular disease, and neurodegenerative disorders.

Potential Drug Target

LY86-AS1 has been identified as a potential drug target due to its various functions in cell signaling pathways. It is a member of the integrin alpha-2 chain, which is involved in cell adhesion, migration, and invasion. LY86-AS1 has been shown to play a role in the regulation of cell proliferation, differentiation, and survival.

Furthermore, LY86-AS1 has been shown to interact with various signaling pathways, including the TGF-β pathway, which is involved in cell growth, differentiation, and survival. LY86-AS1 has been shown to regulate the activity of the transcription factor SMAD, which is involved in the regulation of gene expression.

In addition, LY86-AS1 has also been shown to interact with the protein kinase PDGFR-尾, which is involved in cell signaling pathways, including angiogenesis and cancer progression.

Potential Biomarker

LY86-AS1 has also been identified as a potential biomarker for various diseases, including cancer, cardiovascular disease, and neurodegenerative disorders.

In cancer, LY86-AS1 has been shown to be overexpressed in various types of cancer, including breast, ovarian, and colorectal cancer. It has also been shown to be associated with poor prognosis in cancer patients.

In cardiovascular disease, LY86-AS1 has been shown to be overexpressed in various types of cardiovascular disease, including myocardial infarction, hypertension, and stroke. It has also been shown to be associated with poor prognosis in cardiovascular disease patients.

In neurodegenerative disorders, LY86-AS1 has been shown to be overexpressed in various types of neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. It has also been shown to be associated with poor prognosis in neurodegenerative disorder patients.

Conclusion

LY86-AS1 is a cell surface glycoprotein that has been identified as a potential drug target and biomarker for various diseases, including cancer, cardiovascular disease, and neurodegenerative disorders. Further research is needed to fully understand the role of LY86-AS1 in disease progression and the development of new treatments.

Protein Name: LY86 Antisense RNA 1

The "LY86-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LY86-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets